Autoimmune disease therapeutics sales will expand through 2035, with dermatology indications at 32.0% within the indication segment and immunomodulators and immunosuppressants at 38.0% of the treatment category in 2025. The market was valued at USD 168.6 billion in 2025 and is forecast to record a 3.0% CAGR between 2025 and 2035.